Neurofascin-155 as a putative antigen in combined central and peripheral demyelination
Open Access
- 1 August 2016
- journal article
- editorial
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 3 (4) , e238
Abstract
Combined central and peripheral demyelination (CCPD) encompasses a wide array of disorders ranging from myeloradiculoneuritis and encephalomyeloradiculoneuritis, which often occur after infection or vaccination, to co-occurrence of multiple sclerosis (MS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).1,2 Acknowledgment: The authors thank Dr. Isabel Illa (Hospital de la Santa Creu I Sant Pau de Barcelona, Universitat Autònoma de Barcelona, Spain) for providing the control NF155-positive CIDP serum; Dr. Fabio Blandini (C. Mondino National Neurological Institute, IRCCS, Pavia, Italy) for providing the rat sciatic nerves; and Dr. Emilio Ciusani (IRCCS Foundation, C. Besta Neurological Institute, Milan, Italy) for contributing with CCPD sera collection.Keywords
This publication has 7 references indexed in Scilit:
- Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathyNeurology, 2016
- A nationwide survey of combined central and peripheral demyelination in JapanJournal of Neurology, Neurosurgery & Psychiatry, 2015
- Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIgNeurology, 2014
- Anti-neurofascin antibody in patients with combined central and peripheral demyelinationNeurology, 2013
- Postinfectious neurologic syndromesNeurology, 2013
- Neurofascin as a target for autoantibodies in peripheral neuropathiesNeurology, 2012
- Autoimmune disorders affecting both the central and peripheral nervous systemAutoimmunity Reviews, 2012